FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits. There are differences, however.

Oral semaglutide adds a pill-based option for chronic obesity care without changing the core GLP-1 tradeoffs in efficacy and ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Tru Niagen features Niagen, the most efficient and high-quality NAD+ booster available, backed by more than 40 peer-reviewed human clinical studies. Niagen Bioscience holds a robust intellectual ...

Novo Nordisk is worried about competition and wants to be seen as the cool kid... by using a 20-year-old ad format.

U.S. airline companies stand to save hundreds of millions each year from Americans losing weight thanks to GLP-1 drugs, ...

One of the biggest risk factors for prediabetes is weight gain. Over the past several decades, rates of obesity have risen ...

Many patients taking obesity and diabetes drugs like Ozempic and Wegovy have found its benefits go beyond weight loss.